Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

Acute pulmonary dysfunction remains a frequent and severe complication of hematopoietic stem cell transplantation (SCT). Almost half of the pulmonary insults that occur in this seating are noninfectious in origin and are referred to as idiopathic pneumonia syndrome (IPS). In this series of 3 patient...

Full description

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2002-01, Vol.8 (7), p.395-400
Main Authors: Yanik, Gregory, Hellerstedt, Beth, Custer, Joseph, Hutchinson, Raymond, Kwon, Deborah, Ferrara, James L.M, Uberti, Joseph, Cooke, Kenneth R
Format: Article
Language:English
Subjects:
Adolescent
Bone Marrow Transplantation - adverse effects
Drug Combinations
Drug Evaluation
Etanercept
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Immunoglobulin G - administration & dosage
Male
Neoplasms - complications
Neoplasms - therapy
Peripheral Blood Stem Cell Transplantation - adverse effects
Pneumonia - drug therapy
Pneumonia - etiology
Pneumonia - pathology
Receptors, Tumor Necrosis Factor - administration & dosage
Respiratory Function Tests
Transplantation, Homologous - adverse effects
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute pulmonary dysfunction remains a frequent and severe complication of hematopoietic stem cell transplantation (SCT). Almost half of the pulmonary insults that occur in this seating are noninfectious in origin and are referred to as idiopathic pneumonia syndrome (IPS). In this series of 3 patients, etanercept (Enbrel; Immunex, Seattle, WA), a soluble, dimeric tumor necrosis factor alpha-binding protein, was administered to 3 consecutive pediatric allogeneic BMT recipients with IPS. The administration of etanercept, in combination with standard immunosuppressive therapy, was well tolerated and associated with significant improvements in pulmonary dysfunction within the first week of therapy. These data suggest that etanercept may represent a safe, non-cross-reactive, therapeutic option for patients with IPS and that clinical trials studying etanercept for this indication are warranted. Biol Blood Marrow Transplant 2002;8(7):395-400.
ISSN:1083-8791
1523-6536
DOI:10.1053/bbmt.2002.v8.pm12171486